<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01198548</url>
  </required_header>
  <id_info>
    <org_study_id>I 176910</org_study_id>
    <secondary_id>NCI-2010-01783</secondary_id>
    <nct_id>NCT01198548</nct_id>
  </id_info>
  <brief_title>High-Dose Cholecalciferol in Treating Patients Receiving Combination Chemotherapy and Bevacizumab as First-Line Therapy For Metastatic Colorectal Cancer</brief_title>
  <official_title>A Phase II Clinical Trial of High Dose Vitamin D3 Supplementation in Combination With FOLFOX + Bevacizumab in the 1st Line Treatment of Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well giving high-dose cholecalciferol works in treating
      patients receiving combination chemotherapy and bevacizumab as first-line therapy for
      metastatic colorectal cancer. Cholecalciferol during treatment may delay the development of
      colorectal cancer. Drugs used in chemotherapy, such as leucovorin calcium, fluorouracil, and
      oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the
      cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can
      block tumor growth in different ways. Some block the ability of tumor cells to grow and
      spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.
      Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor.
      Giving cholecalciferol together with combination chemotherapy and monoclonal antibody therapy
      may be an effective treatment for colorectal cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the relative rate of metastatic colorectal cancer patients who achieve 25-D3
      levels &gt;= 40 ng/ml at 8 weeks, 16 weeks, 24 weeks, and 32 weeks from starting FOLFOX
      (leucovorin calcium, fluorouracil, and oxaliplatin) + bevacizumab + high dose vitamin D3
      supplementation (cholecalciferol).

      II. To estimate the median progression-free survival (PFS) of metastatic colorectal cancer
      patients receiving first-line FOLFOX + bevacizumab + high dose vitamin D3 supplementation.

      SECONDARY OBJECTIVES:

      I. To estimate the response rate (RR) and the median overall survival (OS) of metastatic
      colorectal cancer patients receiving first-line FOLFOX + bevacizumab + high dose vitamin D3
      supplementation.

      II. To describe the safety of this combination by capturing all treatment-related toxicity as
      per National Cancer Institute-Common Terminology Criteria (NCI-CTC) version 4 guidelines.

      OUTLINE:

      Patients receive high-dose cholecalciferol orally (PO) once daily. Patients also receive
      bevacizumab intravenously (IV) over 10 minutes, leucovorin calcium IV over 2 hours,
      oxaliplatin* IV over 2 hours, and fluorouracil IV continuously over 46 hours once a week.
      Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.

      NOTE: *Treatment with oxaliplatin is discontinued after course 8.

      After completion of study treatment, patients are followed up at day 30 and then 3 months
      thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of funding
  </why_stopped>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median PFS</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>The estimated distributions of PFS will be obtained using the product-limit based Kaplan-Meier method. The corresponding 95% confidence intervals for the estimated probability will be computed using the method proposed in Clopper and Pearson.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Sufficient Cholecalciferol</measure>
    <time_frame>By week 16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>RR of Patients Receiving Study Treatment</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity Rates as Assessed by NCI CTCAE Version 4</measure>
    <time_frame>Up to 30 days post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS of Patients Receiving Study Treatment</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The estimated distribution of OS will be obtained using the product-limit based Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS of Patients Receiving Study Treatment</measure>
    <time_frame>Defined as the time from the start of the study treatment until the date of progression or death from any cause, whichever comes first, assessed up to 3 years</time_frame>
    <description>The estimated distributions of PFS will be obtained using the product-limit based Kaplan-Meier method.
3 Year Survival Rate</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Stage IV Colon Cancer</condition>
  <condition>Stage IV Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (FOLXFOX, bevacizumab, cholecalciferol)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive high-dose cholecalciferol once daily. Patients also receive bevacizumab IV over 10 minutes, leucovorin calcium IV over 2 hours, oxaliplatin* IV over 2 hours, and fluorouracil IV continuously over 46 hours once a week. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. NOTE: *Treatment with oxaliplatin is discontinued after course 8</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (FOLXFOX, bevacizumab, cholecalciferol)</arm_group_label>
    <other_name>CF</other_name>
    <other_name>CFR</other_name>
    <other_name>LV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (FOLXFOX, bevacizumab, cholecalciferol)</arm_group_label>
    <other_name>anti-VEGF humanized monoclonal antibody</other_name>
    <other_name>anti-VEGF monoclonal antibody</other_name>
    <other_name>Avastin</other_name>
    <other_name>rhuMAb VEGF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>cholecalciferol</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (FOLXFOX, bevacizumab, cholecalciferol)</arm_group_label>
    <other_name>Calciol</other_name>
    <other_name>Vitamin D3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (FOLXFOX, bevacizumab, cholecalciferol)</arm_group_label>
    <other_name>5-fluorouracil</other_name>
    <other_name>5-Fluracil</other_name>
    <other_name>5-FU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (FOLXFOX, bevacizumab, cholecalciferol)</arm_group_label>
    <other_name>1-OHP</other_name>
    <other_name>Dacotin</other_name>
    <other_name>Dacplat</other_name>
    <other_name>Eloxatin</other_name>
    <other_name>L-OHP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (FOLXFOX, bevacizumab, cholecalciferol)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients should have untreated metastatic colorectal cancer; prior adjuvant
             chemotherapy is allowed as long as the development of metastatic disease occurred more
             than 6 months from completion of adjuvant treatment

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1

          -  Platelets &gt;= 100,000/mm^3

          -  Absolute neutrophil count (ANC) &gt;= 1,500/mm^3

          -  Hemoglobin &gt; 9 gm/dl

          -  Calculated creatinine clearance &gt; 40 ml/min according to the Cockcroft-Gault formula
             OR per 24 hour urine collection

          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &lt; 2.5 x
             institutional upper normal level if no liver metastases and &lt; 5 x upper limit of
             normal (ULN) in the setting of liver metastases

          -  Total bilirubin =&lt; 1.5 x institutional upper normal level

          -  Albumin &gt;= 2.5 g/dl

          -  Urine protein:creatinine (UPC) ratio &lt; 1; in the event UPC is &gt; 1, the patient will
             require a 24-hr urine protein and will be eligible if 24-hr urine collection has &lt;
             1,000 mg protein

          -  Patients of child-hearing potential must agree to use acceptable contraceptive methods
             (e.g., double harrier) during treatment

          -  Patient or legal representative must understand the investigational nature of this
             study and sign an Independent Ethics Committee/Institutional Review Board-approved
             written informed consent form prior to receiving any study-related procedure

          -  Presence of measurable disease defined as a lesion &gt;= 1 cm by computed tomography
             (CT); all sites of disease should be evaluated =&lt; 3 weeks before treatment initiation

          -  Baseline 25-D3 level of &lt; 40 ng/ml

        Exclusion Criteria:

          -  Patients may not be receiving any other investigational agents that are not included
             in this study

          -  Patients with known brain metastases

          -  History of other invasive cancers with the exception of the following: a. Curatively
             resected or treated non-melanoma skin cancer; b. Curatively treated cervical carcinoma
             in situ; c. Other primary solid tumors treated curatively and no treatment
             administered &gt;= 2 years before enrollment, and in the investigator opinion, it is
             unlikely that there will be a recurrence =&lt; 1 year post enrollment

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to oxaliplatin, 5-FU, leucovorin, bevacizumab, and vitamin D3 and other
             agents used in study

          -  History of clinically significant bleeding within 6 months of enrollment

          -  Clinically significant cardiovascular disease within 12 months prior to enrollment,
             including myocardial infarction, unstable angina, grade 2 or greater peripheral
             vascular disease, cerebrovascular accident, transient ischemic attack, congestive
             heart failure or arrhythmias not controlled by outpatient medication, percutaneous
             transluminal coronary angioplasty/stent

          -  Pregnant women are excluded from this study; breastfeeding should be discontinued if
             the mother is treated on this study

          -  Major surgery within 28 days prior to enrollment or still recovering from prior
             surgery

          -  Known dihydropyrimidine dehydrogenase (DpD) deficiency

          -  History or evidence upon physical examination of central nervous system (CNS) disease
             (e.g., primary brain tumor, seizures not controlled with standard medical therapy, any
             brain metastases, or history of stroke)

          -  Serious, nonhealing wound, ulcer, or bone fracture

          -  Uncontrolled hypertension (systolic blood pressure &gt; 150 mmHg or diastolic blood
             pressure &gt; 95 mmHg despite medications)

          -  History of arterial thrombosis within the last 12 months

          -  History of visceral arterial ischemia

          -  Subjects unwilling or unable to comply with study requirements

          -  Any condition that in the Investigator's opinion deems the patient an unsuitable
             candidate to receive study drug

          -  Received an investigational agent within 30 clays prior to enrollment

          -  Treatment with vitamin D replacement with doses exceeding an average of 1000 IU/day
             (vitamin D3) within 60 days prior to enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wen Wee Ma</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2010</study_first_submitted>
  <study_first_submitted_qc>September 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2010</study_first_posted>
  <results_first_submitted>January 28, 2014</results_first_submitted>
  <results_first_submitted_qc>June 23, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 21, 2014</results_first_posted>
  <last_update_submitted>June 23, 2014</last_update_submitted>
  <last_update_submitted_qc>June 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (FOLXFOX, Bevacizumab, Cholecalciferol)</title>
          <description>Patients receive high-dose cholecalciferol once daily. Patients also receive bevacizumab IV over 10 minutes, leucovorin calcium IV over 2 hours, oxaliplatin* IV over 2 hours, and fluorouracil IV continuously over 46 hours once a week. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. NOTE: *Treatment with oxaliplatin is discontinued after course 8
leucovorin calcium: Given IV
bevacizumab: Given IV
cholecalciferol: Given PO
fluorouracil: Given IV
oxaliplatin: Given IV
pharmacological study: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (FOLXFOX, Bevacizumab, Cholecalciferol)</title>
          <description>Patients receive high-dose cholecalciferol once daily. Patients also receive bevacizumab IV over 10 minutes, leucovorin calcium IV over 2 hours, oxaliplatin* IV over 2 hours, and fluorouracil IV continuously over 46 hours once a week. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. NOTE: *Treatment with oxaliplatin is discontinued after course 8
leucovorin calcium: Given IV
bevacizumab: Given IV
cholecalciferol: Given PO
fluorouracil: Given IV
oxaliplatin: Given IV
pharmacological study: Correlative studies</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" spread="8.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Median PFS</title>
        <description>The estimated distributions of PFS will be obtained using the product-limit based Kaplan-Meier method. The corresponding 95% confidence intervals for the estimated probability will be computed using the method proposed in Clopper and Pearson.</description>
        <time_frame>Up to 12 months</time_frame>
        <population>Due to the study’s early termination and inadequate number of patients, no patients were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (FOLXFOX, Bevacizumab, Cholecalciferol)</title>
            <description>Patients receive high-dose cholecalciferol once daily. Patients also receive bevacizumab IV over 10 minutes, leucovorin calcium IV over 2 hours, oxaliplatin* IV over 2 hours, and fluorouracil IV continuously over 46 hours once a week. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. NOTE: *Treatment with oxaliplatin is discontinued after course 8
leucovorin calcium: Given IV
bevacizumab: Given IV
cholecalciferol: Given PO
fluorouracil: Given IV
oxaliplatin: Given IV
pharmacological study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Median PFS</title>
          <description>The estimated distributions of PFS will be obtained using the product-limit based Kaplan-Meier method. The corresponding 95% confidence intervals for the estimated probability will be computed using the method proposed in Clopper and Pearson.</description>
          <population>Due to the study’s early termination and inadequate number of patients, no patients were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate of Sufficient Cholecalciferol</title>
        <time_frame>By week 16</time_frame>
        <population>Due to the study’s early termination and inadequate number of patients, no patients were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (FOLXFOX, Bevacizumab, Cholecalciferol)</title>
            <description>Patients receive high-dose cholecalciferol once daily. Patients also receive bevacizumab IV over 10 minutes, leucovorin calcium IV over 2 hours, oxaliplatin* IV over 2 hours, and fluorouracil IV continuously over 46 hours once a week. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. NOTE: *Treatment with oxaliplatin is discontinued after course 8
leucovorin calcium: Given IV
bevacizumab: Given IV
cholecalciferol: Given PO
fluorouracil: Given IV
oxaliplatin: Given IV
pharmacological study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Sufficient Cholecalciferol</title>
          <population>Due to the study’s early termination and inadequate number of patients, no patients were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>RR of Patients Receiving Study Treatment</title>
        <time_frame>Up to 3 years</time_frame>
        <population>Trial terminated early. Too few patients to analyze.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (FOLXFOX, Bevacizumab, Cholecalciferol)</title>
            <description>Patients receive high-dose cholecalciferol once daily. Patients also receive bevacizumab IV over 10 minutes, leucovorin calcium IV over 2 hours, oxaliplatin* IV over 2 hours, and fluorouracil IV continuously over 46 hours once a week. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. NOTE: *Treatment with oxaliplatin is discontinued after course 8
leucovorin calcium: Given IV
bevacizumab: Given IV
cholecalciferol: Given PO
fluorouracil: Given IV
oxaliplatin: Given IV
pharmacological study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>RR of Patients Receiving Study Treatment</title>
          <population>Trial terminated early. Too few patients to analyze.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity Rates as Assessed by NCI CTCAE Version 4</title>
        <time_frame>Up to 30 days post-treatment</time_frame>
        <population>Due to the study’s early termination and inadequate number of patients, no patients were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (FOLXFOX, Bevacizumab, Cholecalciferol)</title>
            <description>Patients receive high-dose cholecalciferol once daily. Patients also receive bevacizumab IV over 10 minutes, leucovorin calcium IV over 2 hours, oxaliplatin* IV over 2 hours, and fluorouracil IV continuously over 46 hours once a week. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. NOTE: *Treatment with oxaliplatin is discontinued after course 8
leucovorin calcium: Given IV
bevacizumab: Given IV
cholecalciferol: Given PO
fluorouracil: Given IV
oxaliplatin: Given IV
pharmacological study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicity Rates as Assessed by NCI CTCAE Version 4</title>
          <population>Due to the study’s early termination and inadequate number of patients, no patients were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OS of Patients Receiving Study Treatment</title>
        <description>The estimated distribution of OS will be obtained using the product-limit based Kaplan-Meier method.</description>
        <time_frame>Up to 3 years</time_frame>
        <population>Due to the study’s early termination and inadequate number of patients, no patients were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (FOLXFOX, Bevacizumab, Cholecalciferol)</title>
            <description>Patients receive high-dose cholecalciferol once daily. Patients also receive bevacizumab IV over 10 minutes, leucovorin calcium IV over 2 hours, oxaliplatin* IV over 2 hours, and fluorouracil IV continuously over 46 hours once a week. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. NOTE: *Treatment with oxaliplatin is discontinued after course 8
leucovorin calcium: Given IV
bevacizumab: Given IV
cholecalciferol: Given PO
fluorouracil: Given IV
oxaliplatin: Given IV
pharmacological study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>OS of Patients Receiving Study Treatment</title>
          <description>The estimated distribution of OS will be obtained using the product-limit based Kaplan-Meier method.</description>
          <population>Due to the study’s early termination and inadequate number of patients, no patients were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS of Patients Receiving Study Treatment</title>
        <description>The estimated distributions of PFS will be obtained using the product-limit based Kaplan-Meier method.
3 Year Survival Rate</description>
        <time_frame>Defined as the time from the start of the study treatment until the date of progression or death from any cause, whichever comes first, assessed up to 3 years</time_frame>
        <population>Due to the study’s early termination and inadequate number of patients, no patients were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (FOLXFOX, Bevacizumab, Cholecalciferol)</title>
            <description>Patients receive high-dose cholecalciferol once daily. Patients also receive bevacizumab IV over 10 minutes, leucovorin calcium IV over 2 hours, oxaliplatin* IV over 2 hours, and fluorouracil IV continuously over 46 hours once a week. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. NOTE: *Treatment with oxaliplatin is discontinued after course 8
leucovorin calcium: Given IV
bevacizumab: Given IV
cholecalciferol: Given PO
fluorouracil: Given IV
oxaliplatin: Given IV
pharmacological study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>PFS of Patients Receiving Study Treatment</title>
          <description>The estimated distributions of PFS will be obtained using the product-limit based Kaplan-Meier method.
3 Year Survival Rate</description>
          <population>Due to the study’s early termination and inadequate number of patients, no patients were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment (FOLXFOX, Bevacizumab, Cholecalciferol)</title>
          <description>Patients receive high-dose cholecalciferol once daily. Patients also receive bevacizumab IV over 10 minutes, leucovorin calcium IV over 2 hours, oxaliplatin* IV over 2 hours, and fluorouracil IV continuously over 46 hours once a week. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. NOTE: *Treatment with oxaliplatin is discontinued after course 8
leucovorin calcium: Given IV
bevacizumab: Given IV
cholecalciferol: Given PO
fluorouracil: Given IV
oxaliplatin: Given IV
pharmacological study: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="12" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="12" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="42" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="48" subjects_affected="6" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="27" subjects_affected="5" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="12" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="16" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Oesophageal pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="22" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="14" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="20" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Blood amylase increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Haemoglobin</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hyperalbuminaemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="12" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Genital pruritus female</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="25" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to the study’s early termination and inadequate number of patients, no patients were analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Administrator, Compliance - Clinical Research Services</name_or_title>
      <organization>Roswell Park Cancer Institute</organization>
      <phone>716-845-2300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

